However, in human organoids, SCFA treatment showed an extra impact on enterochromaffin EC cells and S cells
While the classical incretin concept is based on the assumption that incretin hormones such as GIP and GLP-1 reach their main endocrine target cells via the bloodstream, there is some evidence that GIP (and possibly GLP-1) can be produced in relatively small amounts in endocrine alpha-cells of the pancreas [3]
It has become a cultural talking point about visibility, lifestyle shifts, public curiosity, and how personal change is interpreted in the public eye
These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)
Never attempt to "double up" on doses to compensate for missed injections, as this significantly increases the risk of adverse effects
Your treatment plan is personalized and adjusted over time based on your lab results, medication response, and side effects, so it is never a one-size-fits-all approach
